- This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection. - Subjects will be considered as having completed the study after 60 (+/- 3) days, unless consent withdrawal or death occurs first. - Interim analysis will be permitted as described in the statistical section 8. - The final analysis will be conducted once the last subject completes the day 60 visit or withdraws from the study.
Overall study design
- This is a single arm phase IIa study of convalescent plasma for the treatment of
individuals hospitalized with COVID-19 infection.
- Subjects will be considered as having completed the study after 60 (+/- 3) days, unless
consent withdrawal or death occurs first.
- Interim analysis will be permitted as described in the statistical section 8.
- The final analysis will be conducted once the last subject completes the day 60 visit or
withdraws from the study.
Number of subjects
• Up to 36 patients in track 2, and 19 patients in track 3 as described in the statistical
section 8.
Overall study duration
- The study begins when the first subject (this will likely be a donor) signs the informed
consent. The study will end once the last enrolled subject completes the study (likely a
recipient).
- The expected duration of the study is approximately 12 months.
Biological: Convalescent Plasma
Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
Donor Eligibility Criteria:
- Age 18-60
- A history of a positive nasopharyngeal swab for COVID-19 or a history of positive
titer test.
- At least 14 days from resolution of COVID-19-associated symptoms including fevers
- One negative nasopharyngeal swabs for COVID-19 RNA
- Covid-19 neutralizing antibody >1:64
- Adequate venous access for apheresis
- Meets donor eligibility criteria in accordance to Hackensack University Medical Center
(HUMC) Collection Facility at the John Theurer Cancer Center (JTCC) if collecting at
the JTCC, and all regulatory agencies as describes in SOP 800 01 (Appendix A)
- Required testing of the donor and product must be performed in accordance to FDA
regulations (21 CFR 610.40), and the donation must be found suitable (21 CFR 630.30)
Recipient Eligibility Criteria:
Recipients age >18 years old, are assigned to one of two clinical tracks, track 2 or 3,
based on COVID-19 disease severity. Onset of first symptoms < 9 days.
Track 2:
- Hospitalized, moderate symptoms requiring medical care for COVID-19 infection
- Symptoms may include fever, dyspnea, dehydration among others
- Hypoxemia may be present but is not a requirement
Track 3:
- Requiring mechanical ventilation for the care of COVID-19 infection
- Requiring non-invasive positive pressure ventilation (NIPPV), such as continuous
airway pressure (CPAP),bi-level positive airway pressure (BiPAP) or high flow nasal
canula (HFNC).
Recipient exclusion criteria:
- History of severe transfusion reaction to plasma products
- Infusion of immune globulin within the previous 30 days
- AST or ALT > 10 x upper limit of normal
- Requirement for vasopressors
- COVID-19-associated acute kidney injury requiring dialysis
- DNR status
Hackensack University Medical Center
Hackensack, New Jersey, United States
Michele L Donato, MD, Principal Investigator
Hackensack Meridian Health